Rabbivac–B
Attenuated vaccine against rabbit myxomatosis
The vaccine is intended for the prevention of rabbit myxomatosis in a safe zone, as well as in threatened and dysfunctional farms.
The vaccine provides the formation of an immune response in rabbits to myxomatosis 5-9 days after a single application of 12 months.
Attenuated feline rhinotracheitis herpesvirus (FHV strain F2) Inactivated feline calicivirus antigens (FCV strains 431 and G1) Attenuated Chlamydophila felis (strain 905) Attenuated feline panleukopenia virus (PLI IV)
Attenuated Distemper Virus, BA5 Strain Attenuated Canine Adenovirus Type 2, DK13 Strain Attenuated Canine Parvovirus Type 2, CAG2 Strain Attenuated Parainfluenza Virus Type 2
Attenuated feline rhinotracheitis virus (herpesvirus strain FHV F2), Inactivated feline calicivirus antigens (strains FCV 431 and G1), Attenuated feline panleukopenia virus (strain PLI IV)
Attenuated feline rhinotracheitis virus (herpesvirus strain FHV F2) Inactivated feline calicivirus antigens (strains FCV 431 and G1) Attenuated Chlamydophila felis (strain 905) Attenuated feline panleukopenia virus (strain PLI IV)
Rabies virus, strain G52 (Pasteur)
injectable suspension for pigs
injectable suspension for swin
INGELVAC PRRSFLEX EU 50ml
injectable suspension for pigs
Vaccine against rabbit hemorrhagic disease
